A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer

Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies

(2010) E. L. Mayer et al.   CLINICAL CANCER RESEARCH

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

(2010) N. P. Shah et al.   HAEMATOLOGICA

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals

(2009) Xiang H.-F. Zhang et al.   CANCER CELL

Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling

(2009) Jyoti Nautiyal et al.   CANCER LETTERS

Therapeutic options for metastatic breast cancer

(2009) Patrick G Morris et al.   EXPERT OPINION ON PHARMACOTHERAPY

Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR- : clinical activity and biological correlations

(2008) M. Cristofanilli et al.   ANNALS OF ONCOLOGY

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

(2008) Andrew D. Seidman et al.   JOURNAL OF CLINICAL ONCOLOGY